On 14 October 2025, the fourth exercise period for Bio-Works Technologies AB's ("Bio-Works" or the "Company") warrants of series TO 2 ("TO 2") ended. The TO 2 were issued in connection with the Company’s rights issue of units in August 2024 (the "Rights Issue"). Today the Company announces that a total of 17,854,180 TO 2 were exercised during the fourth exercise period for subscription of 17,854,180 new shares in the Company. Bio-Works thus receives SEK 17,854,180 before issue costs.

"The strong interest shown during the recently concluded exercise of warrants demonstrates the market’s confidence in Bio-Works’ determined efforts to achieve profitable growth. I would like to thank the shareholders who chose to exercise their warrants, and I look forward to new successes." says Lone Carlbom, CEO of Bio-Works.

Outcome from exercise period 4 of 11

During the exercise period 1-14 October 2025, holders of TO 2 were entitled to subscribe for one (1) new share in Bio-Works at a subscription price of SEK 1 per share. During this exercise period, a total of 17,854,180 TO 2 were exercised for subscription of 17,854,180 new shares in the Company. Bio-Works thus receives SEK 17,854,180 before issue-related costs. Conversion from interim shares to ordinary shares is expected to take place around 28 October 2025, and ordinary shares are expected to be visible on each subscriber's custody account approximately two banking days thereafter.

Shares, warrants and share capital

The exercise of TO 2 means that the number of shares in the Company will increase by 17,854,180 shares to a total of 98,225,122, and the Company’s share capital will increase by SEK 1,785,418.0 to SEK 9,822,512.2. Shareholders who have not exercised any TO 2 will experience a dilution of approximately 18.2 percent of the votes and share capital in the Company.

The number of TO 2 that have not yet been exercised, and which will continue to trade on Spotlight Stock Market is 18,714,248.

Next opportunity to exercise TO 2

Exercise of TO 2 for subscription of new shares, can take place during the first ten (10) trading days during each quarter from Q1 2025 up to and including Q3 2027, i.e., on a total of eleven (11) occasions. Each TO 2 can only be exercised for subscription of one new share in the Company and on one occasion only.

Next opportunity to exercise TO 2 for subscription of new shares in Bio-Works is 2 – 16 January 2026.

Advisors

In connection with the exercise of warrants, Sedermera Corporate Finance is the financial advisor (www.sedermera.se), Foyen Advokatfirma acts as legal advisor (www.foyen.se) and Nordic Issuing AB acts as the issuing agent (www.nordic-issuing.se).

Contact details

For more information about the Company, please visit Bio-Works' website, www.bio-works.com, or contact Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, telephone: +46 (0) 8 - 502 705 83.

For further information about TO 2, please contact:

Sedermera Corporate Finance
Telephone: +46 40 615 14 10
E-mail:  cf@sedermera.se 
Website: www.sedermera.se

About Bio-Works

Bio-Works helps the Biotechnology industry to achieve its goals for the purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for Bioprocessing. Our vision is to be a trusted and dynamic partner for a growing and evolving industry.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park, Uppsala, Sweden. We supply our products to a global market, through a combination of direct sales and distributors in Europe, North America and Asia. The Company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For further information please contact us, www.bio-works.com.

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

IMPORTANT INFORMATION

This press release does not constitute an offer to acquire, subscribe or otherwise trade in shares, warrants, or other securities in Bio-Works Technologies AB. Investors should not subscribe for or acquire any securities other than on the basis of the information in the prospectus published prior to the start of the subscription period in the Rights Issue. No action has been taken or will be taken to authorize a public offering in any jurisdiction other than Sweden.

This press release may not be announced, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, the United Kingdom, South Africa, South Korea, Russia, Belarus or in any other jurisdiction where the distribution of this press release would be unlawful. This press release does not constitute an offer to sell new shares, warrants or other securities to any person in any jurisdiction in which it would be unlawful to make such an offer to such person or in which such action would require a prospectus, additional registration or other measures other than under Swedish law. The Prospectus and other documents relating to the Rights Issue and exercise of TO 2 may not be distributed in or into any country where such distribution would require measures set out in the preceding sentence or where they would be contrary to the rules of such country. Any action contrary to this instruction may constitute a violation of applicable securities laws.

No shares, warrants or other securities have been or will be registered under the United States Securities Act of 1933, as amended (the ‘Securities Act’), or the securities laws of any state or other jurisdiction of the United States and may not be offered, subscribed for, exercised, pledged, sold, resold, assigned, delivered or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United States.

This press release may contain certain forward-looking statements that reflect the Company's current views with respect to future events and financial and operational performance. Words such as ‘intends’, ‘estimates’, ‘anticipates’, ‘may’, ‘plans’, ‘believes’, ‘estimates’ and other expressions that are indicative or predictive of future developments or trends, and that are not based on historical facts, constitute forward-looking statements. By its nature, forward-looking information involves known and unknown risks and uncertainties because it is dependent on future events and circumstances. Forward-looking statements are not guarantees of future performance or development and actual results may differ materially from those expressed in the forward-looking statements. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or the rules of Spotlight Stock Market.

DISCLOSURE TO INVESTORS PURSUANT TO THE ACT (2023:560) ON THE SCREENING OF FOREIGN DIRECT INVESTMENTS

The Act (2023:560) on the Screening of Foreign Direct Investments ("FDI Act") applies to the company's operations. In the event that the subscription of new shares by exercise of warrants would result in an investor, after the investment, directly or indirectly, holding votes representing or exceeding any of the thresholds of 10, 20, 30, 50, 65, or 90 percent of the votes in the company, the investor is required to notify their investment to the Inspectorate for Strategic Products in accordance with the FDI Act.